Molecular structure of Fexaramine, CAS Number: 574013-66-4
Fexaramine (CAS 574013-66-4)
See product citations (1)
Alternate Names:
3-[3-[(cyclohexylcarbonyl)[[4′-(dimethylamino)[1,1′-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid, methyl ester
Application:
Fexaramine is a potent, selective FXR activator
CAS Number:
574013-66-4
Purity:
≥97%
Molecular Weight:
496.64
Molecular Formula:
C32H36N2O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Available in US only.
Available in US only.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Fexaramine is a potent, selective FXR (farnesoid X receptor) agonist (EC50 = 25 nM). Fexaramine displays no activity at hRXRα, hPPARα, hPPARγ, hPPARδ, mPXR, hPXR, hLXRα, hTRβ, hRARβ, mCAR, mERRγ and hVDR receptors.
Fexaramine (CAS 574013-66-4) References
- A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. | Downes, M., et al. 2003. Mol Cell. 11: 1079-92. PMID: 12718892
- 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators. | Honório, KM., et al. 2007. J Mol Graph Model. 25: 921-7. PMID: 17055759
- [Progress in the ligands and their complex structures of farnesoid X receptor]. | Li, WH., et al. 2012. Yao Xue Xue Bao. 47: 704-15. PMID: 22919716
- Positive regulation of osteogenesis by bile acid through FXR. | Cho, SW., et al. 2013. J Bone Miner Res. 28: 2109-21. PMID: 23609136
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. | Fang, S., et al. 2015. Nat Med. 21: 159-65. PMID: 25559344
- Obesity and diabetes: FXR and JAK step up to BAT. | Cully, M. 2015. Nat Rev Drug Discov. 14: 91. PMID: 25633788
- Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. | Hartmann, P., et al. 2018. Hepatology. 67: 2150-2166. PMID: 29159825
- Fexaramine Inhibits Receptor Activator of Nuclear Factor-κB Ligand-induced Osteoclast Formation via Nuclear Factor of Activated T Cells Signaling Pathways. | Zheng, T., et al. 2017. J Bone Metab. 24: 207-215. PMID: 29259959
- Farnesoid X receptor agonist decreases lipid accumulation by promoting hepatic fatty acid oxidation in db/db mice. | Liu, Y., et al. 2018. Int J Mol Med. 42: 1723-1731. PMID: 29901078
- Molecular tuning of farnesoid X receptor partial agonism. | Merk, D., et al. 2019. Nat Commun. 10: 2915. PMID: 31266946
- Modulation of the Gut Microbiota-farnesoid X Receptor Axis Improves Deoxycholic Acid-induced Intestinal Inflammation in Mice. | Xu, M., et al. 2021. J Crohns Colitis. 15: 1197-1210. PMID: 33417675
- Ileal FXR-FGF15/19 signaling activation improves skeletal muscle loss in aged mice. | Qiu, Y., et al. 2022. Mech Ageing Dev. 202: 111630. PMID: 35026209
- FXR: structures, biology, and drug development for NASH and fibrosis diseases. | Tian, SY., et al. 2022. Acta Pharmacol Sin. 43: 1120-1132. PMID: 35217809
Inhibitor of:
FXR, and TGR5.Activator of:
FXR, and SHP.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Fexaramine, 10 mg | sc-203580 | 10 mg | $398.00 | |||
| US: Only available in the US | ||||||
Fexaramine, 50 mg | sc-203580A | 50 mg | $1380.00 | |||
| US: Only available in the US | ||||||